A prospective, observational, multicenter cohort study describing the long-term, real-world effectiveness and safety of activated prothrombin complex concentrate (aPCC)
Latest Information Update: 12 Dec 2020
At a glance
- Drugs Factor VIII inhibitor bypassing fraction (Primary)
- Indications Haemophilia A; Haemophilia B; Haemorrhage
- Focus Adverse reactions; Therapeutic Use
- Acronyms FEIBA GO
Most Recent Events
- 07 Dec 2020 According to a Takeda media release, data from this study were presented at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition.
- 02 Dec 2019 New trial record
- 06 Nov 2019 Interim results (corresponding to the report of May 2019.) presented at the 61st Annual Meeting and Exposition of the American Society of Hematology